Nature：寨卡病毒疫苗老鼠试验显示有效

dalc999

单剂量的寨卡病毒疫苗可以保护老鼠免受寨卡病毒感染，该试验结果发表在2016年6月28日的《Nature》上。

　　研究者表示，未来数月内将启动人体临床试验。

　　目前，寨卡病毒在全球60多个国家和地区流行，如中南美洲，最近传播到了亚洲。

　　该病毒可引起妊娠期间胎儿小头畸形，2月1日世界卫生组织宣布其为全球关注的紧急公共卫生事件。

　　来自Walter Reed Army Institute  ofResearch, the Beth Israel Deaconess Medical Center 和Harvard Medical  School的科学家测试了两种疫苗在老鼠中的保护作用。结果发现，两种疫苗均具有很好的保护作用。

　　一种为纯化的灭活疫苗，一种为质粒DNA疫苗。

ipsvirus

Vaccine protection against Zika virus from Brazil

Rafael A. Larocca,        Peter Abbink,        Jean Pierre S. Peron,        Paolo M. de A. Zanotto,        M. Justin Iampietro,        Alexander Badamchi-Zadeh,        Michael Boyd,        David Ng’ang’a,        Marinela Kirilova, Ramya Nityanandam,        Noe B. Mercado,        Zhenfeng Li,        Edward T. Moseley,        Christine A. Bricault,        Erica N. Borducchi,        Patricia B. Giglio,        David Jetton,        George Neubauer,        Joseph P. Nkolola,        Lori F. Maxfield,        Rafael A. De La Barrera,        Richard G. Jarman,        Kenneth H. Eckels, Nelson L. Michael,        Stephen J. Thomas        & Dan H. Barouch

Zika virus (ZIKV) is a flavivirus that is responsible for an unprecedented current epidemic in Brazil and the Americas1,2. ZIKV has been causally associated with fetal microcephaly, intrauterine growth restriction, and other birth defects in both humans3-8 and mice9-11. The rapid development of a safe and effective ZIKV vaccine is a global health priority1,2, but very little is currently known about ZIKV immunology and mechanisms of immune protection. Here we show that a single immunization of a plasmid DNA vaccine or a purified inactivated virus vaccine provides complete protection in susceptible mice against challenge with a ZIKV outbreak strain from northeast Brazil. This ZIKV strain has recently been shown to cross the placenta and to induce fetal microcephaly and other congenital malformations in mice11. We produced DNA vaccines expressing full-length ZIKV pre-membrane and envelope (prM-Env) as well as a series of deletion mutants. The full-length prM-Env DNA vaccine, but not the deletion mutants, afforded complete protection against ZIKV as measured by absence of detectable viremia following challenge, and protective efficacy correlated with Env-specific antibody titers. Adoptive transfer of purified IgG from vaccinated mice conferred passive protection, and CD4 and CD8 T lymphocyte depletion in vaccinated mice did not abrogate protective efficacy. These data demonstrate that protection against ZIKV challenge can be achieved by single-shot subunit and inactivated virus vaccines in mice and that Env-specific antibody titers represent key immunologic correlates of protection. Our findings suggest that the development of a ZIKV vaccine for humans will likely be readily achievable.

http://www.nature.com/nature/jou ... 952.html#affil-auth

Biodog

不错，期待良好的实验结果！